Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania
ML Veronese, K Algazy, L Bearn, B Eaby… - Cancer …, 2005 - Taylor & Francis
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania
ML Veronese, K Algazy, L Bearn… - Cancer …, 2005 - pubmed.ncbi.nlm.nih.gov
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
ML Veronese, K Algazy, L Bearn, B Eaby… - Cancer …, 2005 - europepmc.org
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …